Hussein A M, Jimenez J J, McCall C A, Yunis A A
Department of Medicine, University of Miami School of Medicine, FL 33101.
Science. 1990 Sep 28;249(4976):1564-6. doi: 10.1126/science.2218498.
Alopecia (hair loss) is among the most distressing side effects of cancer chemotherapy. Little progress has been made, however, in its prevention or treatment, partly because of the lack of suitable experimental model. In recent work on the treatment of myelogenous leukemia in the rat, the following observations were made: (i) treatment of 8-day-old rats with cytosine arabinoside consistently produced alopecia, and (ii) ImuVert, a biologic response modifier derived from the bacterium Serratia marcescens, uniformly produced complete protection against the alopecia. In subsequent experiments, both cyclophosphamide and doxorubicin also produced alopecia in this model, and the doxorubicin-induced alopecia was prevented by treatment with ImuVert. The potential relevance of these observations to chemotherapy-induced alopecia in the clinical setting should be examined.
脱发是癌症化疗最令人苦恼的副作用之一。然而，在其预防或治疗方面进展甚微，部分原因是缺乏合适的实验模型。在最近关于大鼠骨髓性白血病治疗的研究中，有以下观察结果：（i）用阿糖胞苷治疗8日龄大鼠会持续导致脱发，以及（ii）一种源自粘质沙雷氏菌的生物反应调节剂ImuVert能始终如一地完全预防脱发。在后续实验中，环磷酰胺和阿霉素在该模型中也会导致脱发，而用ImuVert治疗可预防阿霉素引起的脱发。应研究这些观察结果与临床环境中化疗引起的脱发的潜在相关性。
